JP2008518090A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518090A5 JP2008518090A5 JP2007539188A JP2007539188A JP2008518090A5 JP 2008518090 A5 JP2008518090 A5 JP 2008518090A5 JP 2007539188 A JP2007539188 A JP 2007539188A JP 2007539188 A JP2007539188 A JP 2007539188A JP 2008518090 A5 JP2008518090 A5 JP 2008518090A5
- Authority
- JP
- Japan
- Prior art keywords
- heparin
- medicament
- desulfated
- thrombosis
- platelet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 13
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical class CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims 10
- 102000004965 antibodies Human genes 0.000 claims 6
- 108090001123 antibodies Proteins 0.000 claims 6
- 200000000002 platelet activation Diseases 0.000 claims 5
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 claims 4
- 208000007536 Thrombosis Diseases 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 229960002897 Heparin Drugs 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 claims 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 claims 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 claims 1
- 230000003113 alkalizing Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000000890 antigenic Effects 0.000 claims 1
- 239000004019 antithrombin Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 230000002947 procoagulant Effects 0.000 claims 1
- 239000003805 procoagulant Substances 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 238000005670 sulfation reaction Methods 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
Claims (10)
- 患者において、ヘパリン−血小板第４因子複合体反応性抗体の存在下で血小板活性化または血栓症を誘導することなく、ヘパリン起因性血小板減少症症候群を治療するための医薬であって、有効量の２−Ｏ脱硫酸化ヘパリンを含む医薬。
- 患者において、ヘパリン−血小板第４因子複合体反応性抗体の存在下で血小板活性化または血栓症を誘導することなく、ＨＩＴ抗体とヘパリンに起因する血小板活性化を改善するための医薬であって、有効量の２−Ｏ脱硫酸化ヘパリンを含む医薬。
- ヘパリン起因性血小板減少症を発症するリスクの高い患者において、ヘパリン−血小板第４因子複合体反応性抗体の存在下で血小板活性化または血栓症を誘導することなく、ヘパリン起因性血小板減少症症候群を予防するための医薬であって、有効量の２−Ｏ脱硫酸化ヘパリンを含む医薬。
- 患者において、ヘパリン−血小板第４因子複合体反応性抗体の存在下で血小板活性化または血栓症を誘導することなく、ヘパリン起因性血小板減少症症候群を治療するための医薬であって、有効量の２−Ｏ脱硫酸化ヘパリンと、抗トロンビン薬、抗血小板薬、および抗炎症薬からなる群から選択される薬物とを含む医薬。
- 前記２−Ｏ脱硫酸化ヘパリンが、２−Ｏ、３−Ｏ脱硫酸化ヘパリンである、請求項１〜４のいずれかに記載の医薬。
- 前記２−Ｏ脱硫酸化ヘパリンが、ヘパリンを含有する溶液をｐＨ１３以上にアルカリ化するステップを含む方法によって作製される、請求項１〜４のいずれかに記載の医薬。
- 前記２−Ｏ脱硫酸化ヘパリンが、１単糖あたり約０．６硫酸基以上の平均硫酸化度を有し、２．４ｋＤ以上の平均分子量を有し、生理学的に許容される担体を有する、請求項１〜４のいずれかに記載の医薬。
- 静脈内、皮下、吸入、経口、または経直腸で投与されるものである請求項１〜４のいずれかに記載の医薬。
- 前記有効量が、３ｍｇ／ｋｇ〜１００ｍｇ／ｋｇである、請求項１〜４のいずれかに記載の医薬。
- ＨＩＴ抗体とその抗原決定基との相互作用が積極的に抑制され、その結果生じる血小板凝集およびＨＩＴ症候群に誘導される凝血促進状態が減少する、請求項１〜４のいずれかに記載の医薬。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/974,566 US7468358B2 (en) | 2004-06-16 | 2004-10-27 | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome |
| PCT/US2005/039011 WO2006047755A2 (en) | 2004-10-27 | 2005-10-26 | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (hit) syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008518090A JP2008518090A (ja) | 2008-05-29 |
| JP2008518090A5 true JP2008518090A5 (ja) | 2008-12-11 |
Family
ID=36228513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539188A Pending JP2008518090A (ja) | 2004-10-27 | 2005-10-26 | ヘパリン起因性血小板減少症（ｈｉｔ）症候群の硫酸化多糖類治療のための方法および医薬 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7468358B2 (ja) |
| EP (1) | EP1807095B1 (ja) |
| JP (1) | JP2008518090A (ja) |
| AT (1) | ATE507836T1 (ja) |
| AU (1) | AU2005299568A1 (ja) |
| CA (1) | CA2585640C (ja) |
| DE (1) | DE602005027883D1 (ja) |
| ES (1) | ES2366342T3 (ja) |
| WO (1) | WO2006047755A2 (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050261241A1 (en) | 2004-05-19 | 2005-11-24 | Celsus Biopharmaceuticals, Inc. | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
| WO2008106584A1 (en) * | 2007-02-28 | 2008-09-04 | Paringenix, Inc. | O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease |
| WO2009015183A1 (en) * | 2007-07-23 | 2009-01-29 | University Of Utah Research Foundation | Method for blocking ligation of the receptor for advanced glycation end-products (rage) |
| WO2009117677A2 (en) * | 2008-03-21 | 2009-09-24 | University Of Utah Research Foundation | Methods for controlling intracellular calcium levels associated with an ischemic event |
| ES2939741T3 (es) * | 2009-07-31 | 2023-04-26 | Reliable Biopharmaceutical Llc | Proceso para preparar fondaparinux sódico y productos intermedios útiles en la síntesis del mismo |
| US8420790B2 (en) | 2009-10-30 | 2013-04-16 | Reliable Biopharmaceutical Corporation | Efficient and scalable process for the manufacture of Fondaparinux sodium |
| CA3020369C (en) * | 2010-09-14 | 2019-11-26 | University Of Miyazaki | High purity heparin and production method therefor |
| SG190438A1 (en) * | 2010-12-01 | 2013-07-31 | Univ Australian | Histone inhibition |
| WO2013016181A1 (en) * | 2011-07-22 | 2013-01-31 | Paringenix, Inc. | Compositions and methods for anti-coagulation |
| CA3083488A1 (en) | 2012-02-02 | 2013-08-08 | Reliable Biopharmaceutical Corporation | An efficient and scalable process for the manufacture of fondaparinux sodium |
| AU2016234916A1 (en) * | 2012-05-09 | 2016-11-17 | Cantex Pharmaceuticals, Inc. | Treatment of myelosuppression |
| HUE053247T2 (hu) | 2012-05-09 | 2021-06-28 | Cantex Pharmaceuticals Inc | Mieloszuppresszió kezelése |
| WO2015142924A1 (en) | 2014-03-17 | 2015-09-24 | Cantex Pharmaceuticals, Inc. | Multivalent cation formulations of partially desulfated heparins |
| WO2016133910A1 (en) | 2015-02-17 | 2016-08-25 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
| EP3265828B1 (en) | 2015-03-03 | 2021-04-21 | Laboratory Corporation of America Holdings | Methods and systems for measuring serotonin in a sample |
| CA3102284A1 (en) * | 2018-06-03 | 2019-12-12 | Glycomira Therapeutics, Inc. | Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy |
| GB202006960D0 (en) * | 2020-05-12 | 2020-06-24 | Aplagon Oy | Therapeutic |
| EP4182452A1 (en) | 2020-07-14 | 2023-05-24 | Optimvia, LLC | Methods for synthesizing non-anticoagulant heparan sulfate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2173893T3 (es) * | 1992-07-24 | 2002-11-01 | Thomas P Kennedy | Medicamento que permite inhibir la catepsina g y la elastasa de nuetrofilo. |
| US5668118A (en) | 1992-07-24 | 1997-09-16 | Cavalier Pharmaceuticals | Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G |
| US5696100A (en) * | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
| WO1998004133A1 (en) | 1996-07-29 | 1998-02-05 | Cavalier Pharmaceuticals | Methods of treating asthma with o-desulfated heparin |
| BR9915317A (pt) | 1998-11-13 | 2001-08-07 | Lilly Co Eli | Método de tratar trombocitopenia induzida por heparina |
| EP1223948A2 (en) | 1999-09-13 | 2002-07-24 | CHARLOTTE-MECKLENBURG HOSPITAL doing business as Carolinas Medical Center | Method of inhibiting nf-kappa-b with heparin, for treating cardiovascular diseases and inflammations |
| US6489311B1 (en) | 2000-05-02 | 2002-12-03 | Charlotte-Mecklenburg Hospital Authoirty | Method for the prevention of apoptosis |
| US20080207895A1 (en) | 2002-11-27 | 2008-08-28 | Rosenberg Robert D | Methods for synthesizing polysaccharides |
| US20050261241A1 (en) * | 2004-05-19 | 2005-11-24 | Celsus Biopharmaceuticals, Inc. | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
| US20050282775A1 (en) * | 2004-06-16 | 2005-12-22 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome |
-
2004
- 2004-10-27 US US10/974,566 patent/US7468358B2/en active Active
-
2005
- 2005-10-26 CA CA2585640A patent/CA2585640C/en active Active
- 2005-10-26 AT AT05824840T patent/ATE507836T1/de not_active IP Right Cessation
- 2005-10-26 JP JP2007539188A patent/JP2008518090A/ja active Pending
- 2005-10-26 DE DE602005027883T patent/DE602005027883D1/de active Active
- 2005-10-26 EP EP05824840A patent/EP1807095B1/en active Active
- 2005-10-26 WO PCT/US2005/039011 patent/WO2006047755A2/en active Application Filing
- 2005-10-26 AU AU2005299568A patent/AU2005299568A1/en not_active Abandoned
- 2005-10-26 ES ES05824840T patent/ES2366342T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008518090A5 (ja) | ||
| CA2585640A1 (en) | Use of 2-o desulfated heparin for the treatment of heparin-induced thrombocytopenia (hit) syndrome | |
| AU2013260101B2 (en) | Treatment of myelosuppression | |
| JP2018193377A5 (ja) | ||
| RU2010114051A (ru) | Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств | |
| JP2005520778A5 (ja) | ||
| RU2010114045A (ru) | Применение пептида sfllr-oh и мурамилдипептида в качестве терапевтических средств | |
| RU2010113976A (ru) | Применение glp-1 в качестве терапевтического средства | |
| RU2010113983A (ru) | Применение туфтсина в качестве терапевтического средства | |
| RU2010114044A (ru) | Применение белка полосы 3 (824-829) и/или фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa | |
| JP2012518624A5 (ja) | ||
| Gambaryan et al. | Polymeric inhibitor of influenza virus attachment protects mice from experimental influenza infection | |
| TWI565470B (zh) | 玻尿酸之用途及疼痛抑制用醫藥組成物 | |
| RU2010114030A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114023A (ru) | ПРИМЕНЕНИЕ ПЕПТИДА Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА | |
| JP2006518750A5 (ja) | ||
| JP2010530423A (ja) | 免疫活性化剤を用いたウイルス感染の早期介入 | |
| JP2011519821A5 (ja) | 動脈瘤性くも膜下出血及び血管痙攣に対する医薬組成物 | |
| WO2002074318A1 (fr) | Agents de regulation d'expression d'il-12 | |
| RU2010114052A (ru) | Применение пептида в качестве терапевтического средства | |
| JP2014504613A5 (ja) | ||
| Guo et al. | A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma | |
| HRP20240188T1 (hr) | Konjugat paklitaksel-hijaluronska kiselina u liječenju nemišićno invazivnog raka mjehura | |
| WO2021215987A1 (en) | Compositions and methods for use in the treatment of respiratory infections | |
| RU2010114035A (ru) | Применение rfrp индивидуально или в комбинации с нейрокинином в в качестве терапевтического средства |